天康生物 (002100.SZ)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

利润表(单季度)(天康生物)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2023年第三季度2023年第二季度2023年第一季度2022年第四季度2022年第三季度2022年第二季度2022年第一季度
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表
一、营业总收入(元) 5,742,846,083.365,072,305,821.983,890,843,979.483,846,093,893.024,876,888,188.454,616,696,149.553,391,929,405.09
 营业收入(元) 5,742,846,083.365,072,305,821.983,890,843,979.483,846,093,893.024,876,888,188.454,616,696,149.553,391,929,405.09
二、营业总成本(元) 5,818,030,480.745,501,750,792.163,865,300,990.353,666,037,591.094,522,335,612.684,668,745,063.913,497,856,389.13
 营业成本(元) 5,429,510,004.055,123,496,245.193,549,707,162.093,342,843,007.224,169,863,532.224,317,807,081.343,144,319,839.04
 研发费用(元) 79,442,396.4258,580,416.2240,156,984.4858,716,723.0843,674,827.1240,541,184.0438,129,010.71
 营业税金及附加(元) 12,130,471.6311,253,962.299,863,979.3514,717,314.147,697,769.0910,049,909.516,743,963.52
 销售费用(元) 141,535,640.09142,063,676.88106,983,141.48110,400,367.01131,152,608.33130,756,190.42102,896,660.62
 管理费用(元) 104,906,529.00113,421,606.11104,830,863.2090,439,765.33122,496,133.30117,058,159.92146,883,773.68
 财务费用(元) 50,505,439.5552,934,885.4753,758,859.7548,920,414.3147,450,742.6252,532,538.6858,883,141.56
  其中:利息费用(元) 60,491,941.4168,343,705.2270,835,550.2955,024,454.1744,265,759.6078,443,145.3165,260,259.74
  其中:利息收入(元) 13,949,164.0615,005,922.1715,057,085.6713,766,215.579,192,731.907,652,198.107,096,672.03
 资产减值损失(元) -1,980,115.43---161,433,749.04-7,090,268.7947,726,621.31
 信用减值损失(元) -10,490,499.05-18,663,434.88-21,500,860.35-5,333,609.06-1,592,651.615,619,015.63-44,418,554.09
三、其他经营收益
 加:公允价值变动收益(元) 109,940.00-137,380.0015,270.00--7,920.00462,760.00-516,440.00
 加:投资收益(元) 2,027,877.44389,971.221,139,551.824,250,932.197,070,658.64-2,279,102.578,040,381.48
  其中:对联营企业和合营企业的投资收益(元) 326,743.81153,521.361,139,551.82538,904.877,030,103.631,640,605.294,120,673.62
 资产处置收益(元) 11,322,360.64-2,621,011.32-2,711,470.56-28,628,520.12-1,182,853.01724,564.92104,445.20
 其他收益(元) 22,823,428.504,884,283.368,345,527.0139,017,866.236,579,119.9311,387,686.207,234,780.66
四、营业利润(元) -51,371,405.28-492,976,475.3510,831,007.0527,990,822.13365,418,929.72-29,043,721.39-87,755,749.48
 加:营业外收入(元) 1,150,026.72235,452.62262,711.97686,414.34288,085.88554,768.19150,115.58
 减:营业外支出(元) 18,445,713.279,733,134.517,142,300.5010,789,440.768,749,485.5212,719,249.5110,190,009.50
五、利润总额(元) -68,667,091.83-502,474,157.243,951,418.5217,887,795.71356,957,530.08-41,208,202.71-97,795,643.40
 减:所得税费用(元) -230,260.76741,205.8221,100,463.83-4,117,457.862,726,857.9412,315,842.0410,771,066.79
六、净利润(元) -68,436,831.07-503,215,363.06-17,149,045.3122,005,253.57354,230,672.14-53,524,044.75-108,566,710.19
(一)按经营持续性分类
  持续经营净利润(元) -68,436,831.07-503,215,363.06-17,149,045.3122,005,253.57354,230,672.14-53,524,044.75-108,566,710.19
(二)按所有权归属分类
  归属于母公司股东的净利润(元) -57,093,469.98-433,006,384.38-14,282,251.7643,589,780.64355,439,234.76-27,874,557.29-69,605,796.25
  少数股东损益(元) -11,343,361.09-70,208,978.68-2,866,793.55-21,584,527.07-1,208,562.62-25,649,487.46-38,960,913.94
 扣除非经常性损益后的净利润(元) -71,682,165.00-426,639,377.25-13,686,317.9752,928,888.31362,232,096.57-31,154,984.67-70,071,738.50
七、每股收益
 一、基本每股收益(元) -0.04-0.32-0.010.030.26-0.02-0.05
 二、稀释每股收益(元) -0.04-0.32-0.010.030.26-0.02-0.05
八、其他综合收益(元) -19,676,536.4812,642,401.249,848,219.0723,566,727.9715,240,488.2351,562,348.62-79,575,448.95
 归属于母公司股东的其他综合收益(元) -18,005,033.0811,252,340.629,848,219.0723,365,568.8215,240,488.2351,562,348.62-79,575,448.95
 归属于少数股东的其他综合收益(元) -1,671,503.40------
九、综合收益总额(元) -88,113,367.55-490,572,961.82-7,300,826.2445,571,981.54369,471,160.37-1,961,696.13-188,142,159.14
 归属于母公司所有者的综合收益总额(元) -75,098,503.06-421,754,043.76-4,434,032.6966,955,349.46370,679,722.9923,687,791.33-149,181,245.20
 归属于少数股东的综合收益总额(元) -13,014,864.49-68,818,918.06-2,866,793.55-21,383,367.92-1,208,562.62-25,649,487.46-38,960,913.94
公告日期 2023-10-312023-08-262023-04-292023-04-292022-10-282022-08-242022-04-29
审计意见(境内) 标准无保留意见

前瞻产业研究院